VIRAL SAFETY BY DESIGN FOR CELL AND GENE THERAPY PRODUCTS

DNA assembly is commonly performed in the build step of the design-build-test-learn cycle at the core of synthetic biology. In many assembly workflows, DNA is assembled into gene fragments, which are then assembled into larger constructs, often plasmids.

Industry guidelines for host cell protein impurity analysis emphasize the importance of process-specific and product-specific assessment to account for how the purification procedures and the therapeutic product may uniquely influence the impurities observed. HCP-Mass Spectrometry (HCP-MS) analysis is quickly becoming recognized as a practical, orthogonal approach to ELISA to achieve greater coverage and knowledge of the HCP profile of a biopharmaceutical product. Establishing a streamlined workflow for HCP-MS analysis can be challenging, given that the strategies and rationale for implementing HCP-MS will differ depending on the product, process(es) and other project-specific variables. This webinar will highlight the benefits and the limitations of key analysis criteria for scientists who are developing their HCP-MS detection strategy.

Tune into this webinar and join Form Bio's Head of Solutions Science, Alpha Diallo, PhD and PacBio's Associate Director of Product Marketing, Elizabeth Tseng, PhD to learn about next-gen cell and gene therapy manufacturing.

Watch this on-demand webinar presented by Dr. Akihiko Takashima and Dr. Ioannis (John) Sotiropoulos and learn about the emerging views on the role and function of Tau in neurons - including its recently suggested contributions to scaffolding and signaling.